Strategic Blueprint LLC Has $2.75 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Strategic Blueprint LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,861 shares of the biopharmaceutical company’s stock after selling 226 shares during the period. Strategic Blueprint LLC’s holdings in Regeneron Pharmaceuticals were worth $2,750,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $49,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on REGN. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Finally, Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock opened at $689.31 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $75.75 billion, a price-to-earnings ratio of 17.06, a PEG ratio of 1.59 and a beta of 0.10. The stock has a 50-day moving average of $724.48 and a 200-day moving average of $930.31.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.